Trials / Completed
CompletedNCT03290079
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to: * Assess overall radiographic response rate (ORR) * Assess progression-free survival (PFS) * Test the safety and tolerability of Pembrolizumab in combination with lenvatinib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | 200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle. |
| DRUG | Lenvatinib | 20 mg Lenvatinib by mouth every day of each 3 week cycle |
Timeline
- Start date
- 2017-12-15
- Primary completion
- 2023-01-10
- Completion
- 2024-05-13
- First posted
- 2017-09-21
- Last updated
- 2025-12-22
- Results posted
- 2024-03-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03290079. Inclusion in this directory is not an endorsement.